Windtree Therapeutics Announces Pricing of Upsized $10.8 Million Underwritten Public Offering

WARRINGTON, Pa. , April 20, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced the pricing of its underwritten public offering

Article Date

This article is featured on another website.

Go to article
June 16, 2025

bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies

Marcy l’Étoile, France – June 16th, 2025 – bioMérieux, a world leader in the field of in vitro diagnostics, announces an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections. This strategic acquisition aims to enhance  … Read more

June 16, 2025

bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies

Marcy l’Étoile, France – June 16th, 2025 – bioMérieux, a world leader in the field of in vitro diagnostics, announces an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections. This strategic acquisition aims to enhance  … Read more

June 24, 2025

Revolutionizing the Canavan Disease Treatment Market

Canavan disease, a rare and fatal neurological disorder caused by a mutation in the ASPA gene, leads to a deficiency in the enzyme aspartoacylase.

June 24, 2025

Revolutionizing the Canavan Disease Treatment Market

Canavan disease, a rare and fatal neurological disorder caused by a mutation in the ASPA gene, leads to a deficiency in the enzyme aspartoacylase.